Back to Search Start Over

Risk factors for and characteristics of community- and hospital-acquired drug-induced acute kidney injuries.

Authors :
Rey A
Gras-Champel V
Choukroun G
Masmoudi K
Liabeuf S
Source :
Fundamental & clinical pharmacology [Fundam Clin Pharmacol] 2022 Aug; Vol. 36 (4), pp. 750-761. Date of Electronic Publication: 2022 Jan 25.
Publication Year :
2022

Abstract

Drugs constitute one of the leading causes of acute kidney injuries (AKIs) and can appear in community (CA-AKI) or hospital (HA-AKI) population. The objectives of the present study of a cohort of hospitalized patients with AKI were to describe the characteristics of drug-induced AKIs and the patients' short-term outcomes and assess risk factors for drug-induced AKIs overall, CA-AKIs, and HA-AKIs. Based on a cohort of 1557 hospitalized patients suffering from AKIs based on PMSI extraction and chart review (IRA-PMSI), drug-induced AKIs were identified by applying the Naranjo adverse drug reaction (ADR) probability scale. Multivariate logistic regression was used to identify factors associated with CA-AKIs and/or HA-AKIs. When considering the 1557 patients who experienced an AKI, 445 (28.6%) of the injuries were drug-induced (180 CA-AKIs (40.4%) and 265 HA-AKIs (59.6%)). Antibiotics, diuretics, and contrast agents were significantly more likely to be involved in HA-AKIs, whereas antineoplastic, lipid-lowering drugs, antidiabetics, and immunosuppressive were significantly more likely to be involved in CA-AKIs. Female sex (odds ratio [OR] [95%CI] = 1.3 [1.04-1.67]), chronic kidney disease (CKD) (OR = 1.8 [1.40-2.67]), and a history of ADRs of any type (OR = 1.3 [1.05-1.73]) were significant risk factors for drug-induced AKIs. CKD was a risk factor for both CA-AKI and HA-AKI. In view of the long-term impact of AKI on the kidneys and the differences between our CA-AKI and HA-AKI subgroups, our present results are interesting for optimizing treatments, limiting the occurrence of CA- and HA-AKIs and (ultimately) reducing healthcare costs.<br /> (© 2022 The Authors. Fundamental & Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of Société Française de Pharmacologie et de Thérapeutique.)

Details

Language :
English
ISSN :
1472-8206
Volume :
36
Issue :
4
Database :
MEDLINE
Journal :
Fundamental & clinical pharmacology
Publication Type :
Academic Journal
Accession number :
35037310
Full Text :
https://doi.org/10.1111/fcp.12758